Peptides Similar to Icotrokinra

Overview#

Icotrokinra occupies a unique position at the intersection of two therapeutic categories: IL-23 pathway inhibitors (currently dominated by injectable monoclonal antibodies) and oral targeted therapies for psoriasis (currently limited to deucravacitinib). Understanding how icotrokinra compares with related compounds helps contextualize its potential clinical role.

Injectable IL-23 Inhibitors#

The injectable anti-IL-23 monoclonal antibodies represent the current efficacy benchmark for psoriasis treatment. Icotrokinra targets the same pathway but through a fundamentally different molecular approach (oral macrocyclic peptide vs injectable antibody).

Guselkumab (Tremfya)#

Target: IL-23 p19 subunit (ligand-side blockade)
Administration: 100 mg SC every 8 weeks (after loading)
Molecular type: Monoclonal antibody (~147 kDa)
PASI 90 at 16 weeks: Approximately 70-73%

Risankizumab (Skyrizi)#

Target: IL-23 p19 subunit (ligand-side blockade)
Administration: 150 mg SC every 12 weeks (after loading)
Molecular type: Monoclonal antibody (~146 kDa)
PASI 90 at 16 weeks: Approximately 72-75%

Tildrakizumab (Ilumya)#

Target: IL-23 p19 subunit (ligand-side blockade)
Administration: 100 mg SC every 12 weeks (after loading)
Molecular type: Monoclonal antibody (~147 kDa)
PASI 90 at 16 weeks: Approximately 35-39%

Key Differences from Icotrokinra#

Feature	Icotrokinra	Injectable IL-23 mAbs
Target	IL-23 receptor (receptor-side)	IL-23 p19 subunit (ligand-side)
Administration	Oral tablet, once daily	SC injection every 4-12 weeks
Molecular weight	~1,898 Da	~146,000-147,000 Da
PASI 90 at week 16	50% (ICONIC-LEAD)	35-75% (varies by agent)
Immunogenicity risk	Low (no anti-drug antibodies expected)	Possible anti-drug antibody formation

A critical distinction is that icotrokinra blocks the IL-23 receptor (receptor-side antagonism), while injectable IL-23 mAbs target the IL-23 cytokine itself (ligand-side neutralization). Both approaches prevent IL-23 signaling, but receptor-side blockade is a novel mechanism.

Oral Targeted Therapies for Psoriasis#

Deucravacitinib (Sotyktu)#

Target: TYK2 (allosteric inhibitor)
Administration: 6 mg orally once daily
Molecular type: Small molecule
PASI 75 at 16 weeks: Approximately 53-59%
Direct comparison: Icotrokinra demonstrated superiority over deucravacitinib in ICONIC-ADVANCE 1 & 2

Apremilast (Otezla)#

Target: PDE4 inhibitor
Administration: 30 mg orally twice daily
Molecular type: Small molecule
PASI 75 at 16 weeks: Approximately 29-33%
Note: Lower efficacy than icotrokinra; different mechanism of action

Comparison Table#

Property	Icotrokinra	Guselkumab	Risankizumab	Deucravacitinib
Molecular type	Macrocyclic peptide	Monoclonal antibody	Monoclonal antibody	Small molecule
Target	IL-23R	IL-23 p19	IL-23 p19	TYK2
Route	Oral	SC injection	SC injection	Oral
Frequency	Once daily	Every 8 weeks	Every 12 weeks	Once daily
MW	1,898 Da	147 kDa	146 kDa	490 Da
PASI 90 (wk 16)	50%	~70-73%	~72-75%	~36-40%
Head-to-head	Superior to deucravacitinib	N/A vs icotrokinra	N/A vs icotrokinra	Inferior to icotrokinra

Key Differences#

Icotrokinra vs Injectable IL-23 Inhibitors#

Icotrokinra offers the convenience of oral dosing at the cost of somewhat lower PASI 90 rates at week 16 compared to top-performing injectable IL-23 mAbs. However, responses continue to build beyond week 16, and the oral route may improve real-world adherence and patient preference. Head-to-head trials have not been conducted.

Icotrokinra vs Deucravacitinib#

Both are oral therapies, but icotrokinra demonstrated superiority in the ICONIC-ADVANCE head-to-head trials. Icotrokinra selectively blocks the IL-23 pathway, while deucravacitinib inhibits TYK2, which mediates signaling from multiple cytokines (IL-23, IL-12, type I interferons).

Icotrokinra vs Small Molecule JAK Inhibitors#

JAK inhibitors (tofacitinib, baricitinib) have broad immunosuppressive effects and carry boxed warnings for cardiovascular events, malignancy, and thrombosis. Icotrokinra's selective IL-23R blockade is expected to carry a more targeted safety profile, though long-term data are still maturing.